Form 4: UroGen Pharma Executive Schoenberg Sells Shares to Cover Tax Obligations After RSU Vesting
SEC Form 4 Filing
Chief Medical Officer Mark Schoenberg sold shares of UroGen Pharma to cover withholding tax obligations following the vesting of restricted stock units.
Summary
- Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd., reported changes in beneficial ownership of the company's ordinary shares.
- On June 10, 2024, Schoenberg exercised 10,000 restricted stock units (RSUs), each representing one ordinary share.
- Simultaneously, Schoenberg sold 5,153 shares at a price of $13.08 per share to satisfy withholding tax obligations related to the RSU vesting.
- Following these transactions, Schoenberg directly owns 144,284 ordinary shares and 20,000 RSUs.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing reflects a routine transaction related to executive compensation and tax obligations.
Industry Context
This filing is a routine disclosure of insider transactions. It is common for executives to sell shares to cover tax obligations when stock options or restricted stock units vest. The sale itself doesn't necessarily indicate a negative outlook on the company.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 06/08/2023 | Reporting person was granted RSUs representing 30,000 ordinary shares. |
| 06/10/2024 | Date of RSU exercise and share sale. |
| 06/11/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.